Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) CEO Sells $69,615.00 in Stock

Key Points

• Artiva Biotherapeutics CEO Fred Aslan sold 25,500 shares of the company's stock for $69,615, reducing his position by 6.19% to 386,693 shares.
• The company's stock price increased by 12.7% recently, reaching $3.10, while the stock has fluctuated between a low of $1.47 and a high of $17.31 over the past twelve months.
• Artiva Biotherapeutics reported a quarterly loss of ($0.87) earnings per share, missing estimates, and analysts project a loss of -4.95 EPS for the current year.

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) CEO Fred Aslan sold 25,500 shares of the company's stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $2.73, for a total transaction of $69,615.00. Following the transaction, the chief executive officer owned 386,693 shares in the company, valued at $1,055,671.89. The trade was a 6.19% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Artiva Biotherapeutics Stock Up 12.7%

Shares of NASDAQ:ARTV traded up $0.35 during midday trading on Monday, reaching $3.10. The company's stock had a trading volume of 137,354 shares, compared to its average volume of 137,746. The stock has a fifty day moving average of $2.28 and a 200 day moving average of $2.84. Artiva Biotherapeutics, Inc. has a twelve month low of $1.47 and a twelve month high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.03). As a group, equities research analysts anticipate that Artiva Biotherapeutics, Inc. will post -4.95 EPS for the current year.

Hedge Funds Weigh In On Artiva Biotherapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Wells Fargo & Company MN boosted its holdings in Artiva Biotherapeutics by 64.0% during the fourth quarter. Wells Fargo & Company MN now owns 8,616 shares of the company's stock worth $87,000 after buying an additional 3,361 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in Artiva Biotherapeutics by 262.1% during the fourth quarter. BNP Paribas Financial Markets now owns 9,879 shares of the company's stock worth $100,000 after buying an additional 7,151 shares in the last quarter. Deutsche Bank AG purchased a new stake in Artiva Biotherapeutics during the fourth quarter worth $216,000. Barclays PLC boosted its holdings in Artiva Biotherapeutics by 23.2% during the fourth quarter. Barclays PLC now owns 24,161 shares of the company's stock worth $244,000 after buying an additional 4,545 shares in the last quarter. Finally, Ground Swell Capital LLC purchased a new stake in Artiva Biotherapeutics during the second quarter worth $38,000.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ARTV. Needham & Company LLC cut their price target on shares of Artiva Biotherapeutics from $23.00 to $18.00 and set a "buy" rating on the stock in a research note on Thursday, May 15th. HC Wainwright upgraded shares of Artiva Biotherapeutics to a "buy" rating and set a $12.00 price target on the stock in a research note on Wednesday, June 11th.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.